Multi-institution Analysis of Concurrent Chemoradiation Therapy With Cisplatin (CDDP) Versus Cetuximab (C225) in Locally-Advanced Squamous Cell Carcinoma of the Head and Neck (LA-HNSCC): Can HPV Help Decide Which Agent?
Nadeem Riaz(Memorial Sloan Kettering Cancer Center), Ning‐Yuean Lee(Memorial Sloan Kettering Cancer Center), Peihuang Chen(Beaumont Hospital, Royal Oak), Douglas R. Adkins(Washington University in St. Louis), Wade L. Thorstad(Washington University in St. Louis), Jiayi Huang(Chongqing Medical University), Daniel Krauss(Beaumont Health), Shyam Rao(UC Davis Comprehensive Cancer Center), Jessica Ley(Washington University in St. Louis)
International Journal of Radiation Oncology*Biology*Physics
September 20, 2013
Cited by 3
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
|Nature|2017|1.2k
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
|The Lancet Oncology|2013|748
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
|Journal of the National Comprehensive Cancer Network|2018|632